DefenAge Skincare Granted Patent

Progenitor Biologics LLC, a manufacturer and distributor of the evidence-based, anti-aging skincare products, DefenAge Skincare, has been granted a master patent that covers DefenAge’s core technology by the European Patent Office. The patent is entitled “Stem Cell Stimulating Compositions,” patent number: EP 3157504.
 
The patent protects the exclusive rights of DefenAge to use the spectrum of immune peptides called defensins in topical cosmetic formulations in a specific range of concentrations effective to provide an anti-aging effect on a global scale, specifically to substantially reduce the appearance of wrinkles, pore size, brown and age spots, and redness; to address uneven skin tone and surface imperfections; to improve skin’s brightness, radiance, evenness and clarity; to normalize skin’s oiliness and hydration; and to correct skin firmness, sagging contours, lines and irregularities in texture. 
 
“The key mechanism behind defensins is the messaging to dormant, relatively young and fresh skin’s master stem cells that are located all across our body. When these cells get activated, they produce young, new skin. Our body uses these ‘preserved’ cells during wound healing; therefore, skin in a closed wound is always younger than the skin around the wound. The use of topical defensins on intact skin is a truly revolutionary approach for anti-aging purposes,” explained Gregory Keller, M.D., chairman of DefenAge’s Medical Advisory Board.
 
DefenAge has completed 14 clinical studies to establish the safety and efficacy of their products. The most comprehensive and largest clinical study of defensins is a multi-center, double-blind, placebo-controlled clinical trial. The study showed that the defensin-based skincare regimen globally improved the appearance of aging skin without irritation, dryness or inflammation, and without evidence of an increase of a marker of carcinogenic stimulation. 

“Defensins are a new paradigm in skin care, harnessing the body’s own hidden regenerative powers. The new epidermis is statistically significantly brighter, with less visible superficial and deep wrinkles and vastly reduced appearance of pores. The double-blind study conclusively showed a statistically significant improvement in the global appearance of skin by biopsy, clinical and objective measures,” commented dermatologist Amy Forman Taub, MD, principal investigator of the multi-center clinical trial. The study is published in the Journal of Drugs in Dermatology (2018;17(4):426-441).
 
“With the grant of this patent, DefenAge’s proprietary technology became fully protected in Europe from all angles. The use of defensins for anti-aging purposes is protected by a newly issued patent, and “know-how” protects the specific concentration of defensins, the way of their stabilization and formulation. DefenAge became an exclusive holder of a unique and remarkably powerful skin rejuvenation technology,” commented Nikolay Turovets, DefenAge’s CEO.